Gland Pharma Q4 profit surges 2x on strong US launches, CDMO growth; declares ₹20 dividend

Hyderabad-based drug firm Gland Pharma Ltd on Friday (May 15) reported a 96.6% year-on-year jump in consolidated net profit for the fourth quarter to ₹366.6 crore from ₹186.5 crore in the same period last year, supported by higher revenue and improved operating performance.

Revenue for the quarter rose 22.3% year-on-year to ₹1,742.7 crore compared with ₹1,424.9 crore in the corresponding quarter of the previous year, and full-year FY26 revenue increasing 14.5%.

EBITDA increased 47.6% year-on-year to ₹512.9 crore from ₹347.4 crore. EBITDA margin expanded to 29.4% from 24.4% in the year-ago period and 26% for the full year. Adjusted EBITDA for the quarter increased 51% year-on-year, while full-year adjusted EBITDA rose 33%.

Adjusted PAT jumped 97% year-on-year in the quarter and increased 50% for FY26, with PAT margin improving by 795 basis points in the quarter and 380 basis points for the full year.

R&D investment stood at ₹50.6 crore in Q4FY26 and ₹223 crore for FY26, focused mainly on complex product development and filings. The CDMO business contributed 46% of revenues, growing 36% year-on-year in Q4FY26 and 28% for FY26.

In the base business, revenue also rose 22% year-on-year in the quarter and 11% for FY26. Adjusted EBITDA increased 31% in Q4FY26 and 19% for FY26, while EBITDA margin stood at 41% for the quarter and 38% for the full year.

Adjusted PAT rose 45% in the quarter and 22% for FY26. The base business CDMO segment contributed 25% of revenues in Q4FY26, growing 65% year-on-year, and 23% for FY26 with 33% growth. During the quarter, the company launched five molecules in the US, including Dalbavancin and Brimonidine, taking total FY26 US launches to 31 products.

Eight ANDAs were filed and 11 approved in Q4FY26, while FY26 saw 24 filings and 28 approvals. The cumulative US portfolio stands at 388 ANDA filings, including 337 approvals and 51 pending. The company also reported progress in its complex pipeline, with six products already launched and three awaiting approval. It said complex injectables will remain a key growth driver.

In co-development partnerships, 15 products are under development, including seven 505(b)(2) and eight ANDAs, with commercialisation expected from FY28. The ready-to-use (RTU) infusion bag portfolio included 21 filings and 18 approvals, with 11 additional products under development, addressing an estimated $634 million US market opportunity.

In GLP-1s and insulin analogs, the company launched Liraglutide in the US during FY26, with pen/cartridge capacity at 140 million units annually. The company also signed a complex nano drug delivery system-based injectable oncology contract with a large pharma partner during FY26.

The board recommended a final dividend of ₹20 per equity share for FY26, subject to shareholder approval. Shares of Gland Pharma Ltd ended at ₹1,861.00, down by ₹34.15, or 1.80%, on the BSE.